奇申颗粒调节肠道微生态,改善心力衰竭小鼠的心脏功能
1School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Frontiers in microbiology
|July 3, 2023
概括
奇申颗粒 (QSG) 通过调节肠道微生物群来改善大鼠心力衰竭 (HF). 这种传统中医药可以增强心脏功能和肠道健康,为心力衰竭提供新的治疗点.
科学领域:
- 综合医学是一个整体的医学.
- 心血管研究研究心血管研究
- 微生物组科学 微生物组科学
背景情况:
- 奇申颗粒 (QSG) 是一种经过临床批准的传统中医药,用于心力衰竭 (HF).
- QSG对HF患者肠道微生态的影响尚不清楚.
- 通过肠道微生物群了解QSG的机制,可能会为HF揭示新的治疗策略.
研究的目的:
- 在心力衰竭的小鼠模型中研究QSG对肠道微生态的影响.
- 阐明QSG在通过肠道微生物调节来调节心力衰竭中的潜在机制.
主要方法:
- 通过左冠状动脉绑定建立了心力衰竭的老鼠模型.
- 心脏功能通过心声回声学来评估.
- 用HE和马森染色来评估心脏和肠道病理.
- 用传输电子显微镜检查了线粒体的超结构.
- 用16S rRNA测序分析了肠道微生物组成.
主要成果:
- 在HF大鼠中,QSG的使用改善了心脏功能和心脏组织结构.
- QSG治疗对肠道微生物群进行了积极调节,增加了Bacteroidetes和Prevotellaceae_NK3B31_组的丰度.
- QSG降低了血脂聚糖 (LPS),改善了肠道结构,并恢复了肠道屏障功能.
结论:
- 在老鼠中,QSG通过调节肠道微生态来改善心力衰竭.
- QSG的治疗效果与心脏功能和肠道健康的改善有关.
- 用QSG准肠道微生物群是心力衰竭的有希望的治疗途径.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
635
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
635
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
467
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467
01:22Heart Failure Drugs: Diuretics
424
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
424
01:30Heart Failure V: Medical Management
15
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
15
01:29Cardiomyopathy V: Interprofessional Care
17
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
17
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16